Long-term prognosis in patients undergoing redo-isolated aortic valve replacement

Aleksander Dokollari; Gianluca Torregrossa; Serge Sicouri; Matteo Cameli; Giulia Elena Mandoli; Stephanie Kjelstrom; Edvin Prifti; Altin Veshti; Massimo Bonacchi; Sandro Gelsomino

doi:10.2217/fca-2023-0050

Long-term prognosis in patients undergoing redo-isolated aortic valve replacement

Aleksander Dokollari^*, Gianluca Torregrossa, Serge Sicouri, Matteo Cameli, Giulia Elena Mandoli, Stephanie Kjelstrom, Edvin Prifti, Altin Veshti, Massimo Bonacchi, Sandro Gelsomino

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

To evaluate clinical outcomes after redo aortic valve replacement (AVR) with sutured valves, versus valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), versus sutureless valves. We identified 113 consecutive patients undergoing redo AVR with either ViV-TAVR, redo-sutured and redo-sutureless valves between August 2010 to March 2020. Heart-team made the decision whether patient should undergo redo-sutureless versus ViV-TAVR, versus redo-sutured AVR. Preoperatively, redo-sutured (n = 57), ViV-TAVR (n = 31) and redo-sutureless (n = 25) patients were compared. Postoperatively, after propensity-adjustment analysis, the redo SAVR group had a higher incidence of new postoperative atrial fibrillation (POAF; p = 0.04) compared with redo-sutureless group. Follow-up outcomes analysis did not show differences among groups. Patients undergoing redo-sutureless AVR experienced a higher incidence of POAF compared with patients undergoing redo-sutured.

Original language	English
Article number	fca-2023-0050
Pages (from-to)	685-694
Number of pages	10
Journal	Future Cardiology
Volume	19
Issue number	14
DOIs	https://doi.org/10.2217/fca-2023-0050
Publication status	Published - 11 Dec 2023

Keywords

ViV-TAVR
aorta
bioprosthesis
redo-sutured
redo-sutureless
surgery

Access to Document

10.2217/fca-2023-0050

Cite this

@article{3ab327f764724bf2add355870761b341,

title = "Long-term prognosis in patients undergoing redo-isolated aortic valve replacement",

abstract = "To evaluate clinical outcomes after redo aortic valve replacement (AVR) with sutured valves, versus valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), versus sutureless valves. We identified 113 consecutive patients undergoing redo AVR with either ViV-TAVR, redo-sutured and redo-sutureless valves between August 2010 to March 2020. Heart-team made the decision whether patient should undergo redo-sutureless versus ViV-TAVR, versus redo-sutured AVR. Preoperatively, redo-sutured (n = 57), ViV-TAVR (n = 31) and redo-sutureless (n = 25) patients were compared. Postoperatively, after propensity-adjustment analysis, the redo SAVR group had a higher incidence of new postoperative atrial fibrillation (POAF; p = 0.04) compared with redo-sutureless group. Follow-up outcomes analysis did not show differences among groups. Patients undergoing redo-sutureless AVR experienced a higher incidence of POAF compared with patients undergoing redo-sutured.",

keywords = "ViV-TAVR, aorta, bioprosthesis, redo-sutured, redo-sutureless, surgery",

author = "Aleksander Dokollari and Gianluca Torregrossa and Serge Sicouri and Matteo Cameli and Mandoli, {Giulia Elena} and Stephanie Kjelstrom and Edvin Prifti and Altin Veshti and Massimo Bonacchi and Sandro Gelsomino",

year = "2023",

month = dec,

day = "11",

doi = "10.2217/fca-2023-0050",

language = "English",

volume = "19",

pages = "685--694",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Future Medicine Ltd.",

number = "14",

}

TY - JOUR

T1 - Long-term prognosis in patients undergoing redo-isolated aortic valve replacement

AU - Dokollari, Aleksander

AU - Torregrossa, Gianluca

AU - Sicouri, Serge

AU - Cameli, Matteo

AU - Mandoli, Giulia Elena

AU - Kjelstrom, Stephanie

AU - Prifti, Edvin

AU - Veshti, Altin

AU - Bonacchi, Massimo

AU - Gelsomino, Sandro

PY - 2023/12/11

Y1 - 2023/12/11

N2 - To evaluate clinical outcomes after redo aortic valve replacement (AVR) with sutured valves, versus valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), versus sutureless valves. We identified 113 consecutive patients undergoing redo AVR with either ViV-TAVR, redo-sutured and redo-sutureless valves between August 2010 to March 2020. Heart-team made the decision whether patient should undergo redo-sutureless versus ViV-TAVR, versus redo-sutured AVR. Preoperatively, redo-sutured (n = 57), ViV-TAVR (n = 31) and redo-sutureless (n = 25) patients were compared. Postoperatively, after propensity-adjustment analysis, the redo SAVR group had a higher incidence of new postoperative atrial fibrillation (POAF; p = 0.04) compared with redo-sutureless group. Follow-up outcomes analysis did not show differences among groups. Patients undergoing redo-sutureless AVR experienced a higher incidence of POAF compared with patients undergoing redo-sutured.

AB - To evaluate clinical outcomes after redo aortic valve replacement (AVR) with sutured valves, versus valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), versus sutureless valves. We identified 113 consecutive patients undergoing redo AVR with either ViV-TAVR, redo-sutured and redo-sutureless valves between August 2010 to March 2020. Heart-team made the decision whether patient should undergo redo-sutureless versus ViV-TAVR, versus redo-sutured AVR. Preoperatively, redo-sutured (n = 57), ViV-TAVR (n = 31) and redo-sutureless (n = 25) patients were compared. Postoperatively, after propensity-adjustment analysis, the redo SAVR group had a higher incidence of new postoperative atrial fibrillation (POAF; p = 0.04) compared with redo-sutureless group. Follow-up outcomes analysis did not show differences among groups. Patients undergoing redo-sutureless AVR experienced a higher incidence of POAF compared with patients undergoing redo-sutured.

KW - ViV-TAVR

KW - aorta

KW - bioprosthesis

KW - redo-sutured

KW - redo-sutureless

KW - surgery

U2 - 10.2217/fca-2023-0050

DO - 10.2217/fca-2023-0050

M3 - Article

SN - 1479-6678

VL - 19

SP - 685

EP - 694

JO - Future Cardiology

JF - Future Cardiology

IS - 14

M1 - fca-2023-0050

ER -